Holm Nielsen, Signe
Sun, Shu
Bay-Jensen, Anne C.
Karsdal, Morten
Sørensen, Inge Juul
Weber, Ulrich
Loft, Anne Gitte
Kollerup, Gina
Thamsborg, Gorm
Madsen, Ole Rintek
Møller, Jakob
Østergaard, Mikkel
Pedersen, Susanne Juhl
Article History
Received: 19 August 2022
Accepted: 2 December 2022
First Online: 23 December 2022
Declarations
:
: The study was approved by the regional scientific ethical committee (reference number H-KF-02-050/04) and conducted in accordance with the Helsinki declaration. Informed consent was obtained from all participants.
: Not applicable.
: SHN, SS, ACBJ, and MAK are full-time employees at Nordic Bioscience A/S. Nordic Bioscience is a privately-owned, small–medium size enterprise (SME) partly focused on the development of biomarkers. None of the authors received fees, bonuses, or other benefits for the work described in the manuscript. SHN, MAK, and ACBJ hold stocks in Nordic Bioscience A/S. UW has nothing to disclose. AGL has received research support, consultancy fees, and/or speakers fees from AbbVie, Eli-Lilly, Janssen, MSD, Novartis, Pfizer, and UCB. MØ has received research grants from Abbvie, Amgen, BMS, Merck, Celgene, and Novartis, and speaker and/or consultancy fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Galapagos, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has been an advisory board member for AbbVie and Novartis; received research support from AbbVie, MSD, and Novartis; and received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB.